We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

24 hedge funds and large institutions have $632K invested in MiNK Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% less ownership

Funds ownership: 0.26% → 0.21% (-0.04%)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

17% less funds holding

Funds holding: 29 → 24 (-5)

25% less capital invested

Capital invested by funds: $848K → $632K (-$215K)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
24
Holders Change
-5
Holders Change %
-17.24%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$10.1K
2
GWM
Greenwich Wealth Management
Connecticut
+$9.17K
3
UBS Group
UBS Group
Switzerland
+$2.54K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.38K
5
HighTower Advisors
HighTower Advisors
Illinois
+$882

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$17.9K
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$17.3K
3
Goldman Sachs
Goldman Sachs
New York
-$16.7K
4
Millennium Management
Millennium Management
New York
-$12.5K
5
TRCT
Tower Research Capital (TRC)
New York
-$4.17K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$176K – – –
LF
2
Longbow Finance
Switzerland
$125K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$80K -$17.9K -2,115 -17%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$73.5K +$1.38K +163 +2%
BlackRock
5
BlackRock
New York
$66.1K +$789 +93 +1%
HighTower Advisors
6
HighTower Advisors
Illinois
$36K +$882 +104 +2%
State Street
7
State Street
Massachusetts
$19.1K – – –
CAPTRUST Financial Advisors
8
CAPTRUST Financial Advisors
North Carolina
$11.5K -$17.3K -2,041 -57%
TSS
9
Two Sigma Securities
New York
$8.95K +$10.1K +1,194 New
Northern Trust
10
Northern Trust
Illinois
$8.3K – – –
GWM
11
Greenwich Wealth Management
Connecticut
$8K +$9.17K +1,081 New
Wells Fargo
12
Wells Fargo
California
$7.9K -$280 -33 -3%
UBS Group
13
UBS Group
Switzerland
$4.66K +$2.54K +299 +93%
TRCT
14
Tower Research Capital (TRC)
New York
$3.02K -$4.17K -492 -55%
Bank of America
15
Bank of America
North Carolina
$1.53K – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$1.07K – – –
C
17
Covestor
United Kingdom
$1K -$8 -1 -0.9%
Morgan Stanley
18
Morgan Stanley
New York
$252 -$34 -4 -11%
CCM
19
Chilton Capital Management
Texas
$232 – – –
Northwestern Mutual Wealth Management
20
Northwestern Mutual Wealth Management
Wisconsin
$143 – – –
GPFA
21
Game Plan Financial Advisors
Ohio
$128 – – –
CA
22
Clearstead Advisors
Ohio
$110 – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$97 +$17 +2 +18%
KFI
24
Key Financial Inc
Pennsylvania
$32 – – –
AF
25
Allworth Financial
California
$2 – – –
1
2

INKT Hedge Fund Activity: Q3 2024 in Review

24 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q3 2024, worth a combined $632K — down 25% from $848K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of INKT and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $10.1K. The largest seller was Renaissance Technologies, cutting an estimated $17.9K.

  • 24 institutional investors held MiNK Therapeutics (INKT) as of Q3 2024, down from 29 in Q2 2024.
  • Funds reported $632K of MiNK Therapeutics stock for Q3 2024, down 25% quarter-over-quarter.
  • 2 funds opened new MiNK Therapeutics positions in Q3 2024 and 7 closed out, a net change of -5 holders.
  • The largest MiNK Therapeutics buyer in Q3 2024 was Two Sigma Securities, an estimated $10.1K added.
  • The largest MiNK Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $17.9K sold.

Based on aggregated 13F filings for Q3 2024.